

Remarks/Arguments

Status of the Application

In the Final Office Action mailed September 29, 2007, claims 1-5 and 8-12 were rejected. In the present response, claims 1, 9, 11, and 12 have been amended and claim 10 cancelled. Claims 1-5, 8-9, and 11-12 are now pending.

Support for amending "aryl" to "C₅₋₁₄aryl" in claims 1, 11, and 12 can be found at page 3, lines 9-10.

Support for amending "heteroaryl" to "C₃₋₂₀ heteroaryl" in claims 1, 11, and 12 can be found at page 3, lines 15-18 and page 4, lines 6-7 and 1-2.

Support for adding the language "wherein said aryl and heteroaryl are each independently and optionally substituted with one or more groups selected from C₁₋₆hydrocarbon, -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, oxo (=O), imino (=NR), thio (=S), and oximino (=N-OR), wherein each R is a C₁₋₆hydrocarbyl" to claims 1, 11, and 12 can be found at page 4, line 28 to page 5, line 3.

No new matter has been added.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Rejections Under 35 U.S.C. § 112 first and second paragraphs

Claims 1 and 8-12 were rejected under 35 USC 112, first and second paragraphs. Applicants respectfully submit that the amendments to claims 1 and 11-12, and the cancellation of claim 10 has rendered these rejections moot necessitating their withdrawal. Accordingly, Applicants respectfully request the Examiner to withdraw these rejections.

Objections

Claims 2-5 were objected to as dependent on a rejected base claim. Applicants respectfully submit that the amendments to claim 1 have rendered this objection moot. Accordingly, Applicants respectfully request the Examiner to withdraw this objection.

SUMMARY

In view of the foregoing amendments and remarks, Applicants respectfully submit that the application is in condition for allowance and respectfully solicit a Notice of Allowance. In order to expedite disposition of this case, the Office is invited to contact Applicants'

representative at the telephone number below to resolve any remaining issues. Although Applicants believe no fees other than those accompanying this response are due, the Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100886-1 US.

Respectfully submitted,

/Jacqueline M. Cohen/

Name: Jacqueline M. Cohen
Dated: 9/27/2007
Reg. No.: 51,574
Phone No.: 302-885-4269
Global Intellectual Property,
Patents, AstraZeneca
1800 Concord Pike
Wilmington, DE-19850-5437